Integra LifeSciences Holdings Corporation (NASDAQ:IART) Given Consensus Rating of “Reduce” by Analysts

Integra LifeSciences Holdings Corporation (NASDAQ:IART) has earned a consensus rating of “Reduce” from the six research firms that are covering the company, Marketbeat reports. Three analysts have rated the stock with a sell rating, two have issued a hold rating and one has assigned a buy rating to the company. The average 12 month price objective among brokers that have covered the stock in the last year is $14.40.

A number of equities analysts have issued reports on IART shares. Citigroup lowered their target price on Integra LifeSciences from $11.00 to $9.00 and set a “sell” rating for the company in a report on Wednesday, March 11th. Wall Street Zen cut Integra LifeSciences from a “buy” rating to a “hold” rating in a research report on Saturday, March 7th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Integra LifeSciences in a report on Friday, March 27th. Finally, Wells Fargo & Company raised Integra LifeSciences to a “hold” rating in a research report on Wednesday, March 18th.

Institutional Trading of Integra LifeSciences

Institutional investors have recently made changes to their positions in the business. Rubric Capital Management LP grew its position in Integra LifeSciences by 1.3% in the fourth quarter. Rubric Capital Management LP now owns 7,753,934 shares of the life sciences company’s stock valued at $96,304,000 after purchasing an additional 100,000 shares in the last quarter. Invesco Ltd. lifted its position in Integra LifeSciences by 0.9% during the 4th quarter. Invesco Ltd. now owns 3,522,839 shares of the life sciences company’s stock worth $43,754,000 after buying an additional 31,931 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of Integra LifeSciences by 9.2% during the 3rd quarter. Dimensional Fund Advisors LP now owns 3,184,726 shares of the life sciences company’s stock worth $45,634,000 after buying an additional 267,134 shares during the last quarter. State Street Corp boosted its stake in shares of Integra LifeSciences by 0.8% during the 4th quarter. State Street Corp now owns 2,812,615 shares of the life sciences company’s stock worth $34,933,000 after buying an additional 21,717 shares during the last quarter. Finally, Paradigm Capital Management Inc. NY grew its holdings in shares of Integra LifeSciences by 5.3% in the 4th quarter. Paradigm Capital Management Inc. NY now owns 2,664,998 shares of the life sciences company’s stock valued at $33,099,000 after acquiring an additional 135,198 shares in the last quarter. Institutional investors own 84.78% of the company’s stock.

Integra LifeSciences Stock Performance

Shares of IART stock opened at $9.53 on Friday. The company has a debt-to-equity ratio of 1.66, a quick ratio of 1.46 and a current ratio of 2.54. Integra LifeSciences has a 52 week low of $8.70 and a 52 week high of $21.34. The company’s 50 day moving average price is $10.45 and its two-hundred day moving average price is $12.31. The company has a market capitalization of $742.77 million, a P/E ratio of -1.42 and a beta of 1.06.

Integra LifeSciences (NASDAQ:IART) last released its quarterly earnings results on Thursday, February 26th. The life sciences company reported $0.83 earnings per share for the quarter, beating the consensus estimate of $0.79 by $0.04. The company had revenue of $434.93 million during the quarter, compared to analysts’ expectations of $429.62 million. Integra LifeSciences had a negative net margin of 31.58% and a positive return on equity of 14.76%. The business’s quarterly revenue was down 1.7% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.97 earnings per share. Integra LifeSciences has set its Q1 2026 guidance at 0.370-0.450 EPS and its FY 2026 guidance at 2.300-2.400 EPS. On average, analysts expect that Integra LifeSciences will post 2.45 earnings per share for the current fiscal year.

Integra LifeSciences Company Profile

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.